Sanofi Is First To File Biosimilar Insulin Aspart

 
• By Ian Schofield
  
Diabetes
The EMA is assessing the first biosimilar insulin aspart for diabetes • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products